TRAVERE THERAPEUTICS INC (TVTX) Stock Fundamental Analysis
USA - NASDAQ:TVTX - US89422G1076 - Common Stock
35.44 USD
+0.94 (+2.72%)
34.74 USD
-0.7 (-1.98%)
We assign a fundamental rating of 3 out of 10 to TVTX. TVTX was compared to 533 industry peers in the Biotechnology industry. TVTX may be in some trouble as it scores bad on both profitability and health. TVTX is quite expensive at the moment. It does show a decent growth rate.
1. Profitability
1.1 Basic Checks
TVTX had negative earnings in the past year.
TVTX had a negative operating cash flow in the past year.
TVTX had negative earnings in each of the past 5 years.
TVTX had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
The Return On Assets of TVTX (-16.44%) is better than 79.36% of its industry peers.
TVTX has a Return On Equity (-120.36%) which is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -16.44% | ||
| ROE | -120.36% | ||
| ROIC | N/A |
ROA(3y)-36.55%
ROA(5y)-32.15%
ROE(3y)-416.31%
ROE(5y)-277.75%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Gross Margin of TVTX (97.63%) is better than 96.62% of its industry peers.
In the last couple of years the Gross Margin of TVTX has remained more or less at the same level.
The Profit Margin and Operating Margin are not available for TVTX so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 97.63% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.11%
GM growth 5Y-0.07%
2. Health
2.1 Basic Checks
TVTX does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for TVTX has been increased compared to 1 year ago.
TVTX has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, TVTX has a worse debt to assets ratio.
2.2 Solvency
Based on the Altman-Z score of 1.03, we must say that TVTX is in the distress zone and has some risk of bankruptcy.
TVTX has a better Altman-Z score (1.03) than 63.98% of its industry peers.
TVTX has a Debt/Equity ratio of 4.23. This is a high value indicating a heavy dependency on external financing.
The Debt to Equity ratio of TVTX (4.23) is worse than 82.36% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 4.23 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 1.03 |
ROIC/WACCN/A
WACC8.28%
2.3 Liquidity
TVTX has a Current Ratio of 2.75. This indicates that TVTX is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 2.75, TVTX is doing worse than 65.85% of the companies in the same industry.
A Quick Ratio of 2.71 indicates that TVTX has no problem at all paying its short term obligations.
TVTX has a Quick ratio of 2.71. This is in the lower half of the industry: TVTX underperforms 64.92% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.75 | ||
| Quick Ratio | 2.71 |
3. Growth
3.1 Past
TVTX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 75.91%, which is quite impressive.
The Revenue has grown by 114.22% in the past year. This is a very strong growth!
The Revenue has been growing slightly by 5.87% on average over the past years.
EPS 1Y (TTM)75.91%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%140%
Revenue 1Y (TTM)114.22%
Revenue growth 3Y0.82%
Revenue growth 5Y5.87%
Sales Q2Q%162.11%
3.2 Future
Based on estimates for the next years, TVTX will show a very strong growth in Earnings Per Share. The EPS will grow by 28.22% on average per year.
TVTX is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 40.84% yearly.
EPS Next Y77.25%
EPS Next 2Y40.29%
EPS Next 3Y36.29%
EPS Next 5Y28.22%
Revenue Next Year105.69%
Revenue Next 2Y69.84%
Revenue Next 3Y55.64%
Revenue Next 5Y40.84%
3.3 Evolution
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for TVTX. In the last year negative earnings were reported.
Also next year TVTX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A more expensive valuation may be justified as TVTX's earnings are expected to grow with 36.29% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y40.29%
EPS Next 3Y36.29%
5. Dividend
5.1 Amount
TVTX does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
35.44
+0.94 (+2.72%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners116.03%
Inst Owner Change2.74%
Ins Owners0.83%
Ins Owner Change-1.14%
Market Cap3.16B
Revenue(TTM)435.83M
Net Income(TTM)-88.54M
Analysts84.76
Price Target36.41 (2.74%)
Short Float %13.25%
Short Ratio4.74
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)143%
Min EPS beat(2)53.91%
Max EPS beat(2)232.09%
EPS beat(4)3
Avg EPS beat(4)68.35%
Min EPS beat(4)-27.29%
Max EPS beat(4)232.09%
EPS beat(8)4
Avg EPS beat(8)26.91%
EPS beat(12)6
Avg EPS beat(12)-40.48%
EPS beat(16)6
Avg EPS beat(16)-36.6%
Revenue beat(2)2
Avg Revenue beat(2)31.6%
Min Revenue beat(2)11.48%
Max Revenue beat(2)51.72%
Revenue beat(4)3
Avg Revenue beat(4)17.32%
Min Revenue beat(4)-0.02%
Max Revenue beat(4)51.72%
Revenue beat(8)6
Avg Revenue beat(8)9.84%
Revenue beat(12)9
Avg Revenue beat(12)2.67%
Revenue beat(16)9
Avg Revenue beat(16)-7.53%
PT rev (1m)-2.11%
PT rev (3m)6.32%
EPS NQ rev (1m)47.79%
EPS NQ rev (3m)16.03%
EPS NY rev (1m)21.65%
EPS NY rev (3m)15.67%
Revenue NQ rev (1m)18.74%
Revenue NQ rev (3m)24.72%
Revenue NY rev (1m)13.34%
Revenue NY rev (3m)21.6%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 7.25 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 42.94 | ||
| P/tB | N/A | ||
| EV/EBITDA | N/A |
EPS(TTM)-1.06
EYN/A
EPS(NY)-0.13
Fwd EYN/A
FCF(TTM)-1.21
FCFYN/A
OCF(TTM)-0.66
OCFYN/A
SpS4.89
BVpS0.83
TBVpS-0.4
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -16.44% | ||
| ROE | -120.36% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 97.63% | ||
| FCFM | N/A |
ROA(3y)-36.55%
ROA(5y)-32.15%
ROE(3y)-416.31%
ROE(5y)-277.75%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.11%
GM growth 5Y-0.07%
F-Score6
Asset Turnover0.81
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 4.23 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 89.32% | ||
| Cap/Sales | 11.21% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 2.75 | ||
| Quick Ratio | 2.71 | ||
| Altman-Z | 1.03 |
F-Score6
WACC8.28%
ROIC/WACCN/A
Cap/Depr(3y)142.8%
Cap/Depr(5y)123.81%
Cap/Sales(3y)28.66%
Cap/Sales(5y)21.8%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)75.91%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%140%
EPS Next Y77.25%
EPS Next 2Y40.29%
EPS Next 3Y36.29%
EPS Next 5Y28.22%
Revenue 1Y (TTM)114.22%
Revenue growth 3Y0.82%
Revenue growth 5Y5.87%
Sales Q2Q%162.11%
Revenue Next Year105.69%
Revenue Next 2Y69.84%
Revenue Next 3Y55.64%
Revenue Next 5Y40.84%
EBIT growth 1Y67.92%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year78.04%
EBIT Next 3Y39.42%
EBIT Next 5Y34.35%
FCF growth 1Y64.78%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y77.81%
OCF growth 3YN/A
OCF growth 5YN/A
TRAVERE THERAPEUTICS INC / TVTX FAQ
What is the ChartMill fundamental rating of TRAVERE THERAPEUTICS INC (TVTX) stock?
ChartMill assigns a fundamental rating of 3 / 10 to TVTX.
What is the valuation status of TRAVERE THERAPEUTICS INC (TVTX) stock?
ChartMill assigns a valuation rating of 1 / 10 to TRAVERE THERAPEUTICS INC (TVTX). This can be considered as Overvalued.
How profitable is TRAVERE THERAPEUTICS INC (TVTX) stock?
TRAVERE THERAPEUTICS INC (TVTX) has a profitability rating of 2 / 10.
What is the financial health of TRAVERE THERAPEUTICS INC (TVTX) stock?
The financial health rating of TRAVERE THERAPEUTICS INC (TVTX) is 2 / 10.
What is the earnings growth outlook for TRAVERE THERAPEUTICS INC?
The Earnings per Share (EPS) of TRAVERE THERAPEUTICS INC (TVTX) is expected to grow by 77.25% in the next year.